KZA: Kazia sells stake in Noxopharm
Filed with ASX · · 1 page · English
Earlier from Noxopharm
- Noxopharm to expedite Veyonda Clinical Program
- FNN interview with Nox Chief Medical Officer on Interim Data
- Veyonda and Radiotherapy Delivers Clinical Benefits
- Principal Investigator Discusses LuPIN-1 Study
- NOX Receives $3.26M Federal Govt R&D Rebate
Later from Noxopharm
- Veyonda Chemotherapy Enhancement Program to be Expanded
- Idronoxil Confirmed as New Immuno-Oncology Drug
- Veyonda and Immuno-Oncology Effect Explained
- DARRT Treatment Has Lasting Disease Control at Six Months
- LuPIN Trial Demonstrates High Rates of Response
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm